Mary E. Klotman, MD, speaks with Damon Tweedy, MD about how the medical profession can address ongoing concerns about our nation’s mental health.

A large international study led by Duke researchers found that the diabetes drug empagliflozin slowed the time to first hospitalization for heart failure and reduced the total number of subsequent heart failure hospitalizations in patients after they had suffered acute myocardial infarction.

Allan D. Kirk, MD, PhD, FACS, has been awarded the 2024 Flance-Karl Award by the American Surgical Association (ASA). The Flance-Karl Award recognizes surgeons in the U.S. who have made seminal contributions in basic laboratory research which has application to clinical surgery.

A new mathematical model offers hope for better prediction and treatment of Alzheimer’s disease. 

Dr. Klotman shares news about new funding, Match Day, Distinguished Professorships and more.

For Debra Ragland, PhD, who works closely with PhD students in the School of Medicine, addressing issues related to equity, diversity, and inclusion in the biosciences is simple. She says it’s a matter of creating a supportive environment where the students feel heard.

Scientists at Duke University School of Medicine have long probed the mysteries of RNA, with an eye to harnessing its power for new and better therapies for cancer, diabetes, heart disease and more.

Duke Health is part of a multi-institution research team receiving funding from the federal Advanced Research Projects Agency for Health (ARPA-H) to develop an osteoarthritis treatment that regenerates joints.

Four students at the Duke University School of Medicine have been named to the 2023-24 class of the North Carolina Albert Schwe

Palliative care -- relief from symptoms -- significantly improves a patient’s quality of life and eases fatigue, depression and post-traumatic stress symptoms while they are hospitalized for bone marrow transplant.